
|Videos|August 11, 2022
Treatment of Patients Unfit for Intensive Induction with Venetoclax + Azacitidine
Author(s)Hetty E. Carraway, MD, Eytan Stein, MD
Hetty Carraway, MD, highlights the role of venetoclax + azacitidine in the treatment of patients with acute myeloid leukemia who are unfit for intensive induction therapy.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5











































